Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib in advanced or metastatic cervical carcinoma after platinum failure
2019-002184-97Phase 2Completed
- Sponsor
- Centre François Baclesse
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabozantinib in Cervical Cancer (CC), sponsored by Centre François Baclesse. Primary endpoint: Joint primary efficacy and safety endpoints (Bryant-and-Day design). Started Oct 2019; status: completed.
02
Drugs
cabozantinib
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on 2019-002184-97.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002184-97.